Hypoxia induces HIF1α-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy

Breast cancer hypoxia in relation to prognosis and benefit from radiotherapy after breast-conserving surgery in a large, randomised trial with long-term follow-up

(2022) Julia Tutzauer et al.   BRITISH JOURNAL OF CANCER

Hypoxia and the phenomenon of immune exclusion

(2021) Violena Pietrobon et al.   Journal of Translational Medicine

Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion

(2021) Nicole E. Scharping et al.   NATURE IMMUNOLOGY

Modified Hypoxia-Inducible Factor Expression in CD8+ T Cells Increases Antitumor Efficacy

(2021) Pedro Veliça et al.   Cancer Immunology Research

Hypoxia in Breast Cancer—Scientific Translation to Therapeutic and Diagnostic Clinical Applications

(2021) Ying Zhang et al.   Frontiers in Oncology

Analysis and validation of human targets and treatments using a hepatocellular carcinoma‐immune humanized mouse model

(2021) Yue Zhao et al.   HEPATOLOGY

Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling

(2021) Evan W. Weber et al.   SCIENCE

Pancancer survival analysis of cancer hallmark genes

(2021) Ádám Nagy et al.   Scientific Reports

Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck

(2021) Dan P Zandberg et al.   Journal for ImmunoTherapy of Cancer

Not-so-opposite ends of the spectrum: CD8+ T cell dysfunction across chronic infection, cancer and autoimmunity

(2021) Jenna L. Collier et al.   NATURE IMMUNOLOGY

Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity

(2021) Yugang Guo et al.   NATURE IMMUNOLOGY

Pembrolizumab plus chemotherapy as neoadjuvant treatment for high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study

(2020) P. Schmid et al.   ANNALS OF ONCOLOGY

Epigenetic therapy inhibits metastases by disrupting premetastatic niches

(2020) Zhihao Lu et al.   NATURE

Pembrolizumab for Early Triple-Negative Breast Cancer

(2020) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer

(2020) Rita Nanda et al.   JAMA Oncology

Single-Cell RNA Sequencing of Tumor-Infiltrating NK Cells Reveals that Inhibition of Transcription Factor HIF-1α Unleashes NK Cell Activity

(2020) Jing Ni et al.   IMMUNITY

Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy

(2019) Tuba N. Gide et al.   CANCER CELL

Mitochondrial fragmentation limits NK cell-based tumor immunosurveillance

(2019) Xiaohu Zheng et al.   NATURE IMMUNOLOGY

Comparative Profiling of Metastatic 4T1- vs. Non-metastatic Py230-Based Mammary Tumors in an Intraductal Model for Triple-Negative Breast Cancer

(2019) Jonas Steenbrugge et al.   Frontiers in Immunology

Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy

(2018) Yue Zhao et al.   GUT

A Comprehensive Immunologic Portrait of Triple-Negative Breast Cancer

(2018) Zhixian Liu et al.   Translational Oncology

Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy

(2018) Priyamvada Jayaprakash et al.   JOURNAL OF CLINICAL INVESTIGATION

Chromatin states define tumour-specific T cell dysfunction and reprogramming

(2017) Mary Philip et al.   NATURE

HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo

(2017) Laurence Booth et al.   Oncotarget

CD69 is a direct HIF-1α target gene in hypoxia as a mechanism enhancing expression on tumor-infiltrating T lymphocytes

(2017) Sara Labiano et al.   OncoImmunology

Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade

(2016) Joseph L. Benci et al.   CELL

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

(2016) Willy Hugo et al.   CELL

The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction

(2016) Nicole E. Scharping et al.   IMMUNITY

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

(2016) Rita Nanda et al.   JOURNAL OF CLINICAL ONCOLOGY

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

(2016) Giampaolo Bianchini et al.   Nature Reviews Clinical Oncology

Epigenetic Modulators and the New Immunotherapies

(2016) Anthony E. Dear   NEW ENGLAND JOURNAL OF MEDICINE

HIFI-α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer

(2016) Sylvia Mahara et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Hypoxic control of metastasis

(2016) E. B. Rankin et al.   SCIENCE

Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade

(2016) K. E. Pauken et al.   SCIENCE

Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia

(2016) Nicole E. Scharping et al.   Cancer Immunology Research

Immunological mechanisms of the antitumor effects of supplemental oxygenation

(2015) Stephen M. Hatfield et al.   Science Translational Medicine

IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel

(2015) Zhen Ning Wee et al.   Nature Communications

A Mechanism of Hypoxia-Mediated Escape from Adaptive Immunity in Cancer Cells

(2013) I. B. Barsoum et al.   CANCER RESEARCH

Transcriptional regulation by hypoxia inducible factors

(2013) Veronica L. Dengler et al.   CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY

Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function

(2013) Madhusudhanan Sukumar et al.   JOURNAL OF CLINICAL INVESTIGATION

Hypoxia-inducible factors enhance the effector responses of CD8+ T cells to persistent antigen

(2013) Andrew L Doedens et al.   NATURE IMMUNOLOGY

Markers of T Cell Infiltration and Function Associate with Favorable Outcome in Vascularized High-Grade Serous Ovarian Carcinoma

(2013) Katelin N. Townsend et al.   PLoS One

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

Context-Specific Regulation of NF-κB Target Gene Expression by EZH2 in Breast Cancers

(2011) Shuet Theng Lee et al.   MOLECULAR CELL

Triple-negative breast cancer: Present challenges and new perspectives

(2010) Franca Podo et al.   Molecular Oncology

Characterization of an antagonistic switch between histone H3 lysine 27 methylation and acetylation in the transcriptional regulation of Polycomb group target genes

(2010) Diego Pasini et al.   NUCLEIC ACIDS RESEARCH

CBP-mediated acetylation of histone H3 lysine 27 antagonizes Drosophila Polycomb silencing

(2009) F. Tie et al.   DEVELOPMENT

Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1 

(2008) M. Y. Koh et al.   MOLECULAR CANCER THERAPEUTICS

Digoxin and other cardiac glycosides inhibit HIF-1  synthesis and block tumor growth

(2008) H. Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA